The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.
Researchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU
Participants will:
Enteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI
Age≥ 18 years old, no gender restriction;
Meet the criteria for high-risk groups for PEI;
AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;
Estimated duration of enteral nutrition support therapy: ≥7 days;
Patients who have been clearly diagnosed with PEI or chronic persistent PEI;
Patients who have contraindications to enteral nutrition therapy;
Patients with severely impaired liver or kidney function;
Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;
Parallel
Short peptide
DrugShort peptide EN preparations were administered for nutritional support
Protein
DrugNutritional support therapy was administered with protein-type EN preparations
Branched-chain amino acid concentration
Citrulline concentration
Urine 3-methylhistidine concentration
Fecal elastase-1
Serum pancreatic lipase levels
Serum pancreatic amylase levels
Plasma diamine oxidase levels
Click on the lead sponsor to view all of their trials.
Shanghai 10th People's Hospital
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
